8 completed, 1 active not recruiting, 1 terminated, 1 unknown. 11 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 8, Active not recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 7 | Completed 6, Active not recruiting 1 |
Follow Open-angle Glaucoma: new trials by email Literature Review of Open-angle Glaucoma trials Research Report on Open-angle Glaucoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes Bimatoprost Ophthalmic Solution, 0.01%, LUMIGAN® (bimatoprost ophthalmic solution) 0.01% - Open-angle Glaucoma, Ocular Hypertension | Phase 1 | Unknown | Amneal Pharmaceuticals, LLC | 240 | 2024-04-01 | 2024-08-06 |
| A Study of PER-001 in Participants With Open-Angle Glaucoma PER-001 Intravitreal Implant - Low Dose, PER-001 Intravitreal Implant - High Dose, PER-001 Intravitreal Implant - Sham - Open-angle Glaucoma | Phase 1 / Phase 2 | Completed | Perfuse Therapeutics, Inc. | 33 | 2023-05-25 | 2026-06-05 |
| AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension AGN-193408 SR, Lumigan, Sham Administration - Open-angle Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Active not recruiting | AbbVie | 100 | 2020-11-16 | 2026-05-22 |
| Safety and Tolerability of a Prostaglandin Ocular Implant for Treatment of Open Angle Glaucoma PA5108 - Open-angle Glaucoma | Phase 1 | Completed | PolyActiva Pty Ltd | 8 | 2018-07-24 | 2020-09-16 |
| Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma ANX007 - Open-angle Glaucoma | Phase 1 | Completed | Annexon, Inc. | 9 | 2018-03-23 | 2020-08-20 |
| A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension Fixed Combination, Bimatoprost, Timolol - Open-Angle Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Completed | ForSight Vision5, Inc. | 55 | 2016-04-30 | 2019-02-25 |
| Safety and Efficacy of Anti-Oxidants and Anti-inflammatory Agents in Glaucoma and Diabetic Retinopathy GlaucoHealth, GlaucoSelect, Placebo - Open-angle Glaucoma, Diabetic Retinopathy | Phase 1 | Terminated | The New York Eye & Ear Infirmary | 21 | 2016-04-15 | 2021-03-17 |
| A Three Part Study of MGV354 in Ocular Hypertension or Glaucoma MGV354 ophthalmic suspension, MGV354 placebo - Ocular Hypertension, Open-Angle Glaucoma | Phase 1 / Phase 2 | Completed | Alcon Research | 191 | 2016-03-02 | 2018-07-02 |
| Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension DE-112, DE-112 Vehicle Solution, Timolol Maleate Solution - Open-angle Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Completed | Santen Inc. | 147 | 2011-01-01 | 2012-12-17 |
| Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension bimatoprost 20 µg generation 2, bimatoprost 15 µg generation 2, bimatoprost 10 µg generation 2 - Open-Angle Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Completed | Allergan | 109 | 2010-09-23 | 2020-03-30 |
| Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension DE-104 medium concentration, DE-104 high concentration, Placebo - Open-Angle Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Completed | Santen Inc. | 49 | 2009-03-01 | 2011-11-03 |
Glaucoma, Open-Angle (11) · Ocular Hypertension (7) · Diabetic Retinopathy (1) · Glaucoma (1)
Eye Diseases (11) · Glaucoma (10) · Ocular Hypertension (4) · Cardiovascular Diseases (1) · Diabetes Complications (1) · Diabetes Mellitus (1) · Diabetic Angiopathies (1) · Endocrine System Diseases (1) · Retinal Diseases (1) · Vascular Diseases (1)
Bimatoprost (4) · Latanoprost (1) · Timolol (1)
Santen Inc. (2) · AbbVie (1) · Alcon Research (1) · Allergan (1) · Amneal Pharmaceuticals, LLC (1) · Annexon, Inc. (1) · ForSight Vision5, Inc. (1) · Perfuse Therapeutics, Inc. (1) · PolyActiva Pty Ltd (1) · The New York Eye & Ear Infirmary (1)
United States (8) · Australia (2) · Belgium (1) · Brazil (1) · Canada (1) · Germany (1) · Israel (1) · Japan (1) · Panama (1) · Philippines (1) · Singapore (1) · Spain (1)
Eric Humphriss (1) · Michelle Chen, PhD (1) · Nathan Kerr (1) · Phillip Lai, MD (1) · Robert Ritch, MD (1)